CLOSE

Unit of Haematopathology

Director

Stefano Pileri

highlight

The staff of the Haematopathology Unit consists of well-trained pathologists, biology scientists and technicians with previous experience in the specific field.

On technologic grounds, the Unit is on the front-line in both Italy and Worldwide because of the equipment in house and shared with the laboratories of Clinical Haematoncology and Genomics.

What is the Unit of Haematopathology about

The Unit of Haematopathology  is in charge of the tumors of the haematopoietic and lymphoid tissues as well as of the conditions that can be confused with them. The diagnostic algorithm is based on the amalgamation of clinical information, morphology, phenotypic profile, molecular data, and genetic characteristics. The aim is to provide each patient with a report, which allows the usage of personalized, targeted therapies.

To this end, the Unit is integrated with the Laboratory of Haemato-Oncology the Laboratory of Genomics for the application of FISH, FACS analysis and all conventional and advanced molecular technologies, including next generation sequencing. As to the latter, a lymphoma/leukaemia gene chip is under validation, which will allow to predict the sensitivity of each individual patient to both conventional and experimental drugs. Such information can also be used for the development of murine models to test the pharmacologic sensitivity of a given tumor. 

Here you can download a presentation about activities of the Unit of Haematopathology

  • Our staff
     

    Unit of Haematopathology

    Director

    Stefano Pileri

    Staff Unit of Haematopathology

  • clinical trials

    AIRC 5x1000 N.1007: Genetics-driven targeted management of lymphoid malignancies

     

    The project has a translational aim (i.e. the flow of information from the laboratory bench to the patient’s bedside) with special reference to peripheral T-cell lymphomas, which have a very poor response to current conventional chemotherapies. The goals of the study are as follows: 1) understanding of the mechanisms that sustain the growth and chemo-resistance of these neoplasms, 2) development of innovative molecular diagnostic tools, and 3) identification of novel therapeutic targets. As to the latter, a phase IIA clinical trial with Dasatinib is ongoing at present.

     

     

    AIRC Investigator Grant N. 15762: Blastic plasmacytoid dendritic cell neoplasm: from genomics to therapy

     

    The study design and aims are similar to the ones of the previous project, the focus being however on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), an almost invariably fatal condition. So far, the following results have been obtained: 1) identification of the myeloid nature of the tumor, 2) whole exome and targeted sequencing of 16 cases, 3) identification of potential novel therapeutic targets, and 4) development of murine models in cooperation with Dr. Francesco Bertolini to test the efficacy of the latter. Based on preliminary results, the activation phase IIA clinical trial is expected.

  • specialist staff

PARTNERSHIP

Università degli Studi di Milano Ecancer Medical Science IFOM-IEO Campus

CREDITS

Ministero della Salute Joint Commission International Breastcertification bollinirosa

© 2013 Istituto Europeo di Oncologia - via Ripamonti 435 Milano - P.I. 08691440153

IRCCS - ISTITUTO DI RICOVERO E CURA A CARATTERE SCIENTIFICO

facebook IEO googleplus IEO twitter IEO pinterest IEO vimeo IEO